Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/FDA grants RMAT designation to Aspen's Parkinson's cell therapy, speeding development and review process.
CLPT
$12.86
-$2.52 -16.38%

FDA grants RMAT designation to Aspen's Parkinson's cell therapy, speeding development and review process.

Market News
31 Jul 2026
Accesswire
View Source
Bullish
pluang ai news

Aspen Neuroscience received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel, its investigational autologous cell therapy for Parkinson's disease. This designation allows for expedited development and review, including early FDA interactions and potential priority review or accelerated approval. ClearPoint Neuro supports Aspen's ASPIRO clinical trial with its navigation system for precise cell delivery. The RMAT status highlights the therapy's potential to address serious neurodegenerative conditions and may accelerate bringing this innovative treatment to patients.

More News (CLPT)

ClearPoint Neuro reports Q2 2026 revenue growth of 18% and advances in neuro drug delivery technology.

ClearPoint Neuro reports Q2 2026 revenue growth of 18% and advances in neuro drug delivery technology.

ClearPoint Neuro announced its Q2 2026 financial results with $10.9 million in revenue, up 18% year-over-year, driven by growth in neurosurgery navigation and therapy sales. The company is expanding its neuro drug delivery platform, including a new p...

Company Fundamentals
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App